scholarly journals A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption

Medicina ◽  
2021 ◽  
Vol 57 (9) ◽  
pp. 925
Author(s):  
Hannah J. Anderson ◽  
Jason B. Lee
Keyword(s):  
Drug Eruption ◽  
The Body ◽  
Stevens Johnson Syndrome ◽  
Special Focus ◽  
Fixed Drug Eruption ◽  
Causative Drug ◽  
Johnson Syndrome ◽  
Fixed Drug ◽  
Specific Medication ◽  
Cutaneous Adverse Drug Reaction

Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by the onset of rash at a fixed location on the body each time a specific medication is ingested. With each recurrence, the eruption can involve additional sites. Lesions can have overlying vesicles and/or bullae, and when they cover a significant percentage of body surface area, the eruption is referred to as generalized bullous fixed drug eruption (GBFDE). Due to the widespread skin denudation that can be seen in this condition, GBFDE may be confused clinically with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). While treatments described for GBFDE include supportive care, topical and/or systemic steroids, and, recently, cyclosporine, the mainstay of management involves identifying and discontinuing the causative drug. This review article will provide an overview of FDE with an emphasis on its generalized bullous variant.

Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis

2013 ◽  
Vol 168 (4) ◽  
pp. 726-732 ◽  
Author(s):  
S. Lipowicz ◽  
P. Sekula ◽  
S. Ingen-Housz-Oro ◽  
Y. Liss ◽  
B. Sassolas ◽  
...  
Keyword(s):  
Toxic Epidermal Necrolysis ◽  
Drug Eruption ◽  
Stevens Johnson Syndrome ◽  
Fixed Drug Eruption ◽  
Johnson Syndrome ◽  
Fixed Drug

scholarly journals Contrast-induced generalized bullous fixed drug eruption resembling Stevens-Johnson syndrome

2019 ◽  
Vol 32 (4) ◽  
pp. 601-602
Author(s):  
Meredith Gavin ◽  
Leigha Sharp ◽  
Kendra Walker ◽  
Emily Behrens ◽  
Russell Akin ◽  
...  
Keyword(s):  
Drug Eruption ◽  
Stevens Johnson Syndrome ◽  
Fixed Drug Eruption ◽  
Johnson Syndrome ◽  
Fixed Drug

Bullous Fixed Drug Eruption Masquerading as Recurrent Stevens Johnson Syndrome

2015 ◽  
Vol 48 (5) ◽  
pp. 551-554 ◽  
Author(s):  
Farid M. Dharamsi ◽  
Michael D. Michener ◽  
Jennifer Warner Dharamsi
Keyword(s):  
Drug Eruption ◽  
Stevens Johnson Syndrome ◽  
Fixed Drug Eruption ◽  
Johnson Syndrome ◽  
Fixed Drug

scholarly journals Doxycycline induced fixed drug eruption: a case report

2018 ◽  
Vol 7 (11) ◽  
pp. 2264
Author(s):  
Isswariya Anandan ◽  
Nitya Selvaraj ◽  
Suganya Ganesan ◽  
Meher Ali Rajamohammad ◽  
Nalinidevi Jayabalan
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Drug Eruption ◽  
Skin Lesions ◽  
Severity Assessment ◽  
Fixed Drug Eruption ◽  
Skin Reactions ◽  
Dermatological Examination ◽  
Causative Drug ◽  
Fixed Drug

Fixed drug eruption (FDE) is an adverse drug reaction seen with various groups of drugs are antibiotics such as trimethoprim -sulphamethoxazle, pencillin, tetracyclines, non steroidal anti- inflammatory drugs like ibuprofen, aspirin etc. Doxycycline belongs to tetracycline groups of antibiotics. We herein present the case of Doxycycline induced fixed drug eruption. A 35-year - old man presented to our hospital, with a 2-day history of itching and hyperpigmentation over the chest. Patient developed skin lesion 2 days after and he started taking Doxycycline 100 mg twice a day for skin infections. Dermatological examination revealed multiple well defined hyperpigmented patches seen over the anterior aspect of the chest. Doxycycline was discontinued immediately, and the skin lesions resolved spontaneously within 2 weeks. Causality assessment by using Naranjo adverse drug reaction probability scale and WHO Uppsala monitoring scale categorize the reaction as Doxycycline was the probable cause for the adverse drug reaction. Severity assessment by using modified Hartwig and Siegel ADR severity assessment scale labelled the reaction as mild-level 2. The causative drug or drugs and cross reactants should be avoided in future to prevent recurrence of similar skin reactions.

scholarly journals Causative drugs and HLA-B polymorphism in drug-induced Stevens-Johnson syndrome - toxic epidermal necrolysis: A study in five hospitals in Jakarta

2019 ◽  
Author(s):  
Anesia Tania ◽  
Evita Halim Effendi ◽  
Inge Ade Krisanti ◽  
Yulia Ariani
Keyword(s):  
Toxic Epidermal Necrolysis ◽  
Drug Eruption ◽  
Stevens Johnson Syndrome ◽  
Allele Polymorphism ◽  
Exclusion Criteria ◽  
Drug Induced ◽  
Causative Drug ◽  
Johnson Syndrome ◽  
Luminex Technology ◽  
Referral Hospitals

Stevens-Johnson syndrome and toxic epidermal necrolysis is a very rare but lifethreatening form of cutaneous drug eruption. In recent years, several countries in Asia had succeded in preventing carbamazepine induced SJS/TEN by screening for HLA-B*15:02 before prescribing carbamazepine. This study aimed to acquire data regarding causative drugs and HLA-B allele polymorphism in SJS/TEN patient in Jakarta. We acquired data from 5 referral hospitals from March 2015 to March 2017. Subject fulfilling the inclusion and exclusion criteria was interviewed and blood sample was taken for DNA extraction. The DNA was examined with PCR SSOP and Luminex technology for high resolution HLA-B typing. We studied 22 subjects. The median age was 45,4 years old (14-74). The most common causative drug in this study is carbamazepine. HLA-B*15:02 and HLAB* 18:01 were the most common allele in all subjects. HLA-B*15:02 was found in five (72%) out of seven subjects whose condition was caused by carbamazepine. The most common causative drug of SJS/TEN in five hospitals in Jakarta is carbamazepine, with five (72%) out seven subjects had HLA-B*15:02 allele.

Sign in / Sign up

Export Citation Format

Share Document